Fast Market Research

PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023 - New Report Available

Fast Market Research recommends "PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023" from GlobalData, now available

 
Repost This

Boston, MA -- (SBWIRE) -- 06/24/2014 -- PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

View Full Report Details and Table of Contents

The anticipated growth of the depression market in Japan is due to the expected launch of Brintellix and the potential introduction of seven late-stage pipeline products into the market during the forecast period. GlobalData anticipates Elli Lilly's Cymbalta and Lundbeck/Forest (Actavis)/Mitsubishi Tanabe Pharma/Mochida's Lexapro to be the top-selling products by the end of the forecast period in Japan, generating combined sales of approximately $162.2m.

Scope

- Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the Japan Major depressive disorder market.

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in Japan.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023
- PharmaPoint: Major Depressive Disorder - US Drug Forecast and Market Analysis to 2023
- PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023
- Major Depressive Disorder - Pipeline Review, H1 2014
- Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023
- Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023
- Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023
- Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023
- Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023
- Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023